This prompted us to re-impute genetic variant data from the population-based Ovarian Cancer Association Consortium (OCAC)33, and BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)34,35 to assess whether the larger coverage of the genome from the TOPMed reference panel leads to detection of novel loci associated with HGSOC risk. This evidence concerns the gene BRCA1 and ovarian cancer.